During the past two decades the frequencies and types of life-threatening fungal infections
have increased dramatically in immunocompromised patients (7, 220, 232, 282). Several …

Invasive mycoses have become important causes of morbidity and mortality in
immunocompromised patients. New approaches for antifungal therapy are required to meet …

Invasive, life-threatening fungal infections are an important cause of morbidity and mortality,
particularly for patients with compromised immune function. The number of therapeutic …

During the past two decades invasive fungal infections have emerged as major causes of
morbidity and mortality in immunocompromised patients. Several factors have contributed to …

In recent years, incidences of invasive fungal infections have greatly increased, especially in
immunosuppressed patients, but most today's antifungal drugs are not completely effective …

The need for better antifungal therapy is commonly accepted in view of the high mortality
rates associated with systemic infections, the low number of available antifungal classes …

Continued advancement of medical science offers life-saving treatment options for a variety
of hematologic, oncologic, and rheumatologic conditions. Immunosuppression, a common …

With the increasing morbidity and mortality of invasive fungal infections and the emergence
of severe antifungal drug resistance, new drug targets and novel antifungal agents are …

Recent investigations have yielded both profound insights into the mechanisms required by
pathogenic fungi for virulence within the human host, as well as novel potential targets for …

Invasive fungal infections are becoming more common. Current therapy is generally limited
to amphotericin B in its parent and lipid formulations, 5-fluctyosine, fluconazole, and …